Track Nanobiotix S.A. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Nanobiotix S.A. NBTX · Stock Open Nanobiotix S.A. in new tab

30.66 USD
EPS
-1.27
P/B
-44.64
Beta
0.54
Target Price
53.81 USD
Loading chart...
Key Metrics
Earnings dateApril 27, 2027
EPS-1.27
Book Value-0.74
Price to Book-44.64
Growth
Revenue Growth-0.79%
Estimates
Forward P/E-196.45
Forward EPS-0.17
Target Mean Price53.81

DCF valuation

Model fair value for Nanobiotix S.A. (NBTX)
Result
Sign in to run the valuation for NBTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus None · mean target 53.81 USD (low 29.83, high 69.25) · as of 12 Nov 2026
Low 29.83
Mean 53.81
High 69.25
Price 30.66
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Nanobiotix S.A. Logo Nanobiotix S.A. Analysis (NBTX)

France Health Care Official Website Stock

Is Nanobiotix S.A. a good investment? Nanobiotix S.A. (NBTX) is currently trading at 30.66 USD. Market analysts have a consensus price target of 53.81 USD. This suggests a potential upside from current levels.

Earnings Schedule: Nanobiotix S.A. is expected to release its next earnings report on April 27, 2027. The market consensus estimate for Forward EPS is -0.17.

Investor FAQ

Does Nanobiotix S.A. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Nanobiotix S.A.?

Nanobiotix S.A. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be April 27, 2027. The company currently has a trailing EPS of -1.27.

Company Profile

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Exchange Ticker
FRA (Germany) 5NRA.F
NMS (United States) NBTX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion